Donald F.H. Dougan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Donald F.H. Dougan has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
D.N. Wade
7 shared publicationsA.M. Duffield
Biomedical Mass Spectrometry Unit, University of New South Wales, Kensington, N.S.W., 2033, Australia
5 shared publicationsP.H. Duffield
University of New South Wales and Department of Clinical Pharmacology and Toxicology, St. Vincent's Hospital, Darlinghurst, N.S.W. 2010, Australia
5 shared publicationsD. N. Wade
Department of Clinical Pharmacology, St Vincent's Hospital, Darlinghurst, NSW 2010, Australia
4 shared publicationsA. M. Duffield
Biomedical Mass Spectrometry Unit, The University of New South Wales, P.O. Box 1, Kensington, NSW 2033, Australia
1 shared publicationC.G. Meredith
University of New South Wales and Department of Clinical Pharmacology and Toxicology, St. Vincent's Hospital, Darlinghurst, N.S.W. 2010, Australia
1 shared publication
Latest Publications
- 1 January 1987
- Published by Elsevier in Comparative Biochemistry and Physiology Part C: Comparative Pharmacology
- Vol. 86 (2) , 317-324
Modulation of dopamine receptors in the Tapes clam by dextroamphetamine and phenylethanolamine
- 1 January 1987
- Published by Elsevier in Comparative Biochemistry and Physiology Part C: Comparative Pharmacology
- Vol. 86 (2) , 317-324
Modulation of dopamine receptors in the Tapes clam by dextroamphetamine and phenylethanolamine
- Open Access
- 1 May 1986
- Published by Wiley in British Journal of Pharmacology
- Vol. 88 (1) , 285-290
Stereoselective accumulation of hydroxylated metabolites of amphetamine in rat striatum and hypothalamus
The stereoselective accumulation of α‐methyl‐p‐tyramine (AMPT) and α‐methyl‐p‐octopamine (AMPO) in rat striatum and hypothalamus after acute and chronic administration of the (+)‐and (−)‐isomers of amphetamine (Amphet) and the acute administration of (+)‐ and (−)‐AMPT has been investigated by chemical ionization gas chromatography mass spectrometry (c.i.g.c.m.s.). Two h after the administration of (+)‐ or (−)‐AMPT (5 mg kg−1i.p.), the concentrations of the isomers in striatal tissue were approximately equal; 18 h later, the concentration of the (+)‐isomer was 10 times that of the (−)‐isomer. The concentrations of AMPO in the striatum and hypothalamus 20 h after administration of (+)‐AMPT were 68 ng g−1and 484 ng g−1respectively. After the administration of the (−)‐isomer of AMPT, small quantities of AMPO were detected in both brain areas. Twenty h after the last of 7 daily injections of (+)‐Amphet (5 mg kg−1, i.p.), the concentration of AMPO in the hypothalamus was 5.4 times the concentration at 20 h after one injection. In the striatum, the corresponding ratio for AMPO was 3.5 and for AMPT was 2.5. These data indicate that, although both isomers of AMPT formed from Amphet administered systemically, cross the blood brain barrier, the (+)‐isomers AMPT and AMPO are preferentially stored in striatal and hypothalamic aminergic nerve terminals. The accumulations of AMPT and AMPO in rat striatum and hypothalamus after chronic administration of Amphet demonstrates that these metabolites persist in neuronal storage in these brain areas for days after administration. The half‐lives of (+)‐AMPT and (+)‐AMPO in striatal neuronal storage, calculated from this data, were 1.5 days and 2.5 days, respectively. The corresponding half‐life for hypothalamic (+)‐AMPO was 7 days. These findings suggest the involvement of accumulated AMPT and AMPO in the development of behavioural augmentation to repeated injections of Amphet (Randrup & Munkvad, 1970).
- 1 May 1986
- Published by Wiley in British Journal of Pharmacology
- Vol. 88 (1) , 285-290
Open AccessStereoselective accumulation of hydroxylated metabolites of amphetamine in rat striatum and hypothalamus
The stereoselective accumulation of α‐methyl‐p‐tyramine (AMPT) and α‐methyl‐p‐octopamine (AMPO) in rat striatum and hypothalamus after acute and chronic administration of the (+)‐and (−)‐isomers of amphetamine (Amphet) and the acute administration of (+)‐ and (−)‐AMPT has been investigated by chemical ionization gas chromatography mass spectrometry (c.i.g.c.m.s.). Two h after the administration of (+)‐ or (−)‐AMPT (5 mg kg−1i.p.), the concentrations of the isomers in striatal tissue were approximately equal; 18 h later, the concentration of the (+)‐isomer was 10 times that of the (−)‐isomer. The concentrations of AMPO in the striatum and hypothalamus 20 h after administration of (+)‐AMPT were 68 ng g−1and 484 ng g−1respectively. After the administration of the (−)‐isomer of AMPT, small quantities of AMPO were detected in both brain areas. Twenty h after the last of 7 daily injections of (+)‐Amphet (5 mg kg−1, i.p.), the concentration of AMPO in the hypothalamus was 5.4 times the concentration at 20 h after one injection. In the striatum, the corresponding ratio for AMPO was 3.5 and for AMPT was 2.5. These data indicate that, although both isomers of AMPT formed from Amphet administered systemically, cross the blood brain barrier, the (+)‐isomers AMPT and AMPO are preferentially stored in striatal and hypothalamic aminergic nerve terminals. The accumulations of AMPT and AMPO in rat striatum and hypothalamus after chronic administration of Amphet demonstrates that these metabolites persist in neuronal storage in these brain areas for days after administration. The half‐lives of (+)‐AMPT and (+)‐AMPO in striatal neuronal storage, calculated from this data, were 1.5 days and 2.5 days, respectively. The corresponding half‐life for hypothalamic (+)‐AMPO was 7 days. These findings suggest the involvement of accumulated AMPT and AMPO in the development of behavioural augmentation to repeated injections of Amphet (Randrup & Munkvad, 1970).
- 1 April 1986
- Published by Elsevier in Life Sciences
- Vol. 38 (14) , 1271-1280
Effect of chlordimeform and clonidine on the turnover of P-octopamine in rat hypothalamus and striatum
- 1 April 1986
- Published by Elsevier in Life Sciences
- Vol. 38 (14) , 1271-1280
Effect of chlordimeform and clonidine on the turnover of P-octopamine in rat hypothalamus and striatum
- 1 January 1985
- Published by Elsevier in Comparative Biochemistry and Physiology Part C: Comparative Pharmacology
- Vol. 82 (1) , 193-197
Octopamine receptors in the molluscan aortic bulb: Effects of clozapine and chlordimeform
- 1 January 1985
- Published by Elsevier in Comparative Biochemistry and Physiology Part C: Comparative Pharmacology
- Vol. 82 (1) , 193-197
Octopamine receptors in the molluscan aortic bulb: Effects of clozapine and chlordimeform
- 1 May 1982
- Published by Elsevier in Life Sciences
- Vol. 30 (20) , 1701-1705
Absence of α-methyldopamine in rat striatum after chronic administration of d-amphetamine
- 1 May 1982
- Published by Elsevier in Life Sciences
- Vol. 30 (20) , 1701-1705
Absence of α-methyldopamine in rat striatum after chronic administration of d-amphetamine
- 31 December 1981
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 2, 113-116
Aminergic neurones, phenolamine pathways and octopamine
- 31 December 1981
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 2, 113-116
Aminergic neurones, phenolamine pathways and octopamine
- 1 April 1981
- Published by Wiley in Journal of Mass Spectrometry
- Vol. 8 (4) , 170-173
A chemical ionization gas chromatographic mass spectrometric assay for octopamine and tyramine in rat brain
- 1 April 1981
- Published by Wiley in Journal of Mass Spectrometry
- Vol. 8 (4) , 170-173
A chemical ionization gas chromatographic mass spectrometric assay for octopamine and tyramine in rat brain
- 1 January 1981
- Published by Elsevier in Comparative Biochemistry and Physiology Part C: Comparative Pharmacology
- Vol. 70 (2) , 277-280
Occurrence and synthesis of octopamine in the heart and ganglia of the mollusc Tapes watlingi
- 1 January 1981
- Published by Elsevier in Comparative Biochemistry and Physiology Part C: Comparative Pharmacology
- Vol. 70 (2) , 277-280
Occurrence and synthesis of octopamine in the heart and ganglia of the mollusc Tapes watlingi
- 1 August 1978
- Published by Wiley in Clinical and Experimental Pharmacology and Physiology
- Vol. 5 (4) , 341-349
DIFFERENTIAL BLOCKADE OF OCTOPAMINE AND DOPAMINE RECEPTORS BY ANALOGUES OF CLOZAPINE AND METOCLOPRAMIDE
1. Sulpiride, but not procainamide, antagonizes the excitatory effects of (±)-octopamine receptors in the Tapes ventricle. Neither compound attenuates dopamine excitation. 2. Clozapine will attenuate the effects of (±)-octopamine and (-)-α-methyl octopamine at the octopamine receptor but not the excitatory effects of dopamine at dopamine receptors. 3. Clozapine is more potent than its 2-positional isomer HF 2046 in attenuating octopamine excitation. However, HF 2046, unlike clozapine, will attenuate the excitatory effects of dopamine. 4. These data indicate that replacement of the 8-chloro substituent in the clozapine nucleus with a 2-chloro substituent decreases the ability of the compound to blockade octopamine receptors. However, the 2-chloro-substituted compound (HF 2046) now has the added ability to blockade excitatory dopamine receptors. 5. The greater potency of clozapine than HF 2046 as an octopamine antagonist suggests that it is the 8-chloro-substituted aromatic ring of clozapine which overlaps the aromatic site usually occupied by the octopamine aromatic ring.
- 1 August 1978
- Published by Wiley in Clinical and Experimental Pharmacology and Physiology
- Vol. 5 (4) , 341-349
DIFFERENTIAL BLOCKADE OF OCTOPAMINE AND DOPAMINE RECEPTORS BY ANALOGUES OF CLOZAPINE AND METOCLOPRAMIDE
1. Sulpiride, but not procainamide, antagonizes the excitatory effects of (±)-octopamine receptors in the Tapes ventricle. Neither compound attenuates dopamine excitation. 2. Clozapine will attenuate the effects of (±)-octopamine and (-)-α-methyl octopamine at the octopamine receptor but not the excitatory effects of dopamine at dopamine receptors. 3. Clozapine is more potent than its 2-positional isomer HF 2046 in attenuating octopamine excitation. However, HF 2046, unlike clozapine, will attenuate the excitatory effects of dopamine. 4. These data indicate that replacement of the 8-chloro substituent in the clozapine nucleus with a 2-chloro substituent decreases the ability of the compound to blockade octopamine receptors. However, the 2-chloro-substituted compound (HF 2046) now has the added ability to blockade excitatory dopamine receptors. 5. The greater potency of clozapine than HF 2046 as an octopamine antagonist suggests that it is the 8-chloro-substituted aromatic ring of clozapine which overlaps the aromatic site usually occupied by the octopamine aromatic ring.